Genentech hired Evotec to help it identify potential small molecule drug candidates in 2010. The agreement was extended for three years in 2013.
Today’s extension will see the collaboration continue through to 2019 and broaden the scope of the research according to Evotec COO, Mario Polywka,
He said the “extension is validation of the value Evotec brings to this partnership. With an increasing portfolio of activities, the scientific teams from both companies are working closely together to effectively and efficiently advance Genentech’s discovery projects.”
A spokeswoman for Evotec told us: "The extension was prompted by the continued value Evotec provides to the Genentech small molecule drug discovery team."